Roche Holding AG (RHHVF)
USD 313.0
(-0.2%)
USD 313.0
(-0.2%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 18.54 Billion CHF | -13.33% |
| 2022 | 21.52 Billion CHF | -5.84% |
| 2021 | 22.86 Billion CHF | 1.6% |
| 2020 | 23.07 Billion CHF | 3.51% |
| 2019 | 21.69 Billion CHF | 19.69% |
| 2018 | 18.5 Billion CHF | 8.09% |
| 2017 | 16.9 Billion CHF | -6.09% |
| 2016 | 17.9 Billion CHF | 4.86% |
| 2015 | 16.74 Billion CHF | 2.62% |
| 2014 | 16.31 Billion CHF | -10.6% |
| 2013 | 18.39 Billion CHF | 9.6% |
| 2012 | 16.24 Billion CHF | 3.68% |
| 2011 | 16.29 Billion CHF | -0.61% |
| 2010 | 16.26 Billion CHF | -10.52% |
| 2009 | 15.5 Billion CHF | 11.69% |
| 2008 | 16.47 Billion CHF | -4.26% |
| 2007 | 18.12 Billion CHF | 20.51% |
| 2006 | 15.34 Billion CHF | 47.53% |
| 2005 | 9.68 Billion CHF | -8.54% |
| 2004 | 10.58 Billion CHF | 49.03% |
| 2003 | 7.1 Billion CHF | 148.76% |
| 2002 | 2.85 Billion CHF | -40.52% |
| 2001 | 4.8 Billion CHF | -51.9% |
| 2000 | 27.57 Billion CHF | 12.45% |
| 1999 | 8.87 Billion CHF | 37.71% |
| 1998 | 6.44 Billion CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 6.16 Billion CHF | 0.0% |
| 2024 Q1 | 6.16 Billion CHF | -28.39% |
| 2023 Q4 | 8.61 Billion CHF | 98.59% |
| 2023 FY | - CHF | -13.33% |
| 2023 Q1 | 6.1 Billion CHF | -37.83% |
| 2023 Q3 | 4.33 Billion CHF | -61.29% |
| 2023 Q2 | 11.2 Billion CHF | 83.48% |
| 2022 Q4 | 9.82 Billion CHF | 93.75% |
| 2022 Q3 | 5.07 Billion CHF | -58.35% |
| 2022 Q2 | 12.17 Billion CHF | 74.79% |
| 2022 FY | - CHF | -5.84% |
| 2022 Q1 | 6.96 Billion CHF | -31.91% |
| 2021 FY | - CHF | 1.6% |
| 2021 Q2 | 11.5 Billion CHF | 81.43% |
| 2021 Q3 | 5.82 Billion CHF | -49.32% |
| 2021 Q4 | 10.23 Billion CHF | 75.53% |
| 2021 Q1 | 6.33 Billion CHF | -38.18% |
| 2020 Q2 | 12.04 Billion CHF | 82.37% |
| 2020 Q1 | 6.6 Billion CHF | -38.77% |
| 2020 Q4 | 10.25 Billion CHF | 91.77% |
| 2020 FY | - CHF | 3.51% |
| 2020 Q3 | 5.34 Billion CHF | -55.6% |
| 2019 Q1 | 6.74 Billion CHF | 31.3% |
| 2019 Q3 | 5.73 Billion CHF | -14.99% |
| 2019 Q4 | 10.78 Billion CHF | 87.94% |
| 2019 FY | - CHF | 19.69% |
| 2019 Q2 | 6.74 Billion CHF | 0.0% |
| 2018 Q4 | 5.14 Billion CHF | 0.0% |
| 2018 FY | - CHF | 8.09% |
| 2018 Q3 | 5.14 Billion CHF | -15.89% |
| 2018 Q2 | 6.11 Billion CHF | 0.0% |
| 2018 Q1 | 6.11 Billion CHF | 25.96% |
| 2017 Q4 | 4.85 Billion CHF | 0.0% |
| 2017 Q3 | 4.85 Billion CHF | -15.47% |
| 2017 Q2 | 5.74 Billion CHF | 0.0% |
| 2017 FY | - CHF | -6.09% |
| 2017 Q1 | 5.74 Billion CHF | 13.04% |
| 2016 Q1 | 5.25 Billion CHF | 14.92% |
| 2016 Q4 | 5.07 Billion CHF | 0.0% |
| 2016 Q3 | 5.07 Billion CHF | -3.3% |
| 2016 Q2 | 5.25 Billion CHF | 0.0% |
| 2016 FY | - CHF | 4.86% |
| 2015 Q2 | 4.95 Billion CHF | 0.0% |
| 2015 FY | - CHF | 2.62% |
| 2015 Q4 | 4.57 Billion CHF | 0.0% |
| 2015 Q3 | 4.57 Billion CHF | -7.76% |
| 2015 Q1 | 4.95 Billion CHF | 9.77% |
| 2014 Q1 | 5.05 Billion CHF | 12.45% |
| 2014 FY | - CHF | -10.6% |
| 2014 Q4 | 4.51 Billion CHF | 0.0% |
| 2014 Q3 | 4.51 Billion CHF | -10.68% |
| 2014 Q2 | 5.05 Billion CHF | 0.0% |
| 2013 Q1 | 5 Billion CHF | 7.16% |
| 2013 Q4 | 4.49 Billion CHF | 0.0% |
| 2013 FY | - CHF | 9.6% |
| 2013 Q2 | 5 Billion CHF | 0.0% |
| 2013 Q3 | 4.49 Billion CHF | -10.16% |
| 2012 FY | - CHF | 3.68% |
| 2012 Q3 | 4.66 Billion CHF | 0.0% |
| 2012 Q4 | 4.66 Billion CHF | 0.0% |
| 2011 FY | - CHF | -0.61% |
| 2010 FY | - CHF | -10.52% |
| 2009 FY | - CHF | 11.69% |
| 2008 FY | - CHF | -4.26% |
| 2007 FY | - CHF | 20.51% |
| 2006 FY | - CHF | 47.53% |
| 2005 FY | - CHF | -8.54% |
| 2004 FY | - CHF | 49.03% |
| 2003 FY | - CHF | 148.76% |
| 2002 FY | - CHF | -40.52% |
| 2001 FY | - CHF | -51.9% |
| 2000 FY | - CHF | 12.45% |
| 1999 FY | - CHF | 37.71% |
| 1998 FY | - CHF | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | -39.507% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | 4.517% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | -1514.891% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 46794.371% |
| Novartis AG | 19.51 Billion USD | 5.01% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | -6334.513% |